Bacterial outer membrane vesicles and vaccine applications

Reinaldo Acevedo, Sonsire Fernandez, Caridad Zayas, Armando Acosta, Maria Elena Sarmiento, Valerie Ferro, Einar Rosenqvist, Concepcion Campa, Daniel Cardoso, Luis Garcia, Jose Luis Perez

Research output: Contribution to journalSpecial issue

85 Citations (Scopus)

Abstract

Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of “self” meningococcal antigens or unrelated antigens incorporated into the vesicle structure. This paper reviews different applications in OMV Research and Development (R&D) and provides examples of OMV developed and evaluated at the Finlay Institute in Cuba. A Good Manufacturing Practice (GMP) process was developed at the Finlay Institute to produce OMV from N. meningitidis serogroup B (dOMVB) using detergent extraction. Subsequently, OMV from N. meningitidis, serogroup A (dOMVA), serogroup W (dOMVW) and serogroup X (dOMVX) were obtained using this process. More recently, the extraction process has also been applied effectively for obtaining OMV on a research scale from Vibrio cholerae (dOMVC), Bordetella pertussis (dOMVBP), Mycobacterium smegmatis (dOMVSM) and BCG (dOMVBCG). The immunogenicity of the OMV have been evaluated for specific antibody induction, and together with functional bactericidal and challenge assays in mice have shown their protective potential. dOMVB has been evaluated with non-self neisserial antigens, including with a herpes virus type 2 glycoprotein, ovalbumin and allergens. In conclusion, OMV are proving to be more versatile than first conceived and remain an important technology for development of vaccine candidates. - See more at: http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00121/abstract#sthash.MwqUyZQ1.dpuf
LanguageEnglish
Number of pages17
JournalFrontiers in Immunology
Volume5
Issue number121
DOIs
Publication statusPublished - 2014

Fingerprint

Vaccines
Membranes
Serogroup B Neisseria meningitidis
Serogroup A Neisseria meningitidis
Mycobacterium smegmatis
Antigens
Bordetella pertussis
Cuba
Vibrio cholerae
Immunomodulation
Ovalbumin
Autoantigens
Mycobacterium bovis
Research
Detergents
Allergens
Glycoproteins
Viruses
Technology
Antibodies

Keywords

  • bacterial
  • outer membrane
  • vesicles
  • vaccine applications

Cite this

Acevedo, R., Fernandez, S., Zayas, C., Acosta, A., Sarmiento, M. E., Ferro, V., ... Perez, J. L. (2014). Bacterial outer membrane vesicles and vaccine applications. Frontiers in Immunology, 5(121). https://doi.org/10.3389/fimmu.2014.00121#sthash.MwqUyZQ1.dpuf
Acevedo, Reinaldo ; Fernandez, Sonsire ; Zayas, Caridad ; Acosta, Armando ; Sarmiento, Maria Elena ; Ferro, Valerie ; Rosenqvist, Einar ; Campa, Concepcion ; Cardoso, Daniel ; Garcia, Luis ; Perez, Jose Luis. / Bacterial outer membrane vesicles and vaccine applications. In: Frontiers in Immunology. 2014 ; Vol. 5, No. 121.
@article{87a67692a7064eb485b09cd3feb4f810,
title = "Bacterial outer membrane vesicles and vaccine applications",
abstract = "Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of “self” meningococcal antigens or unrelated antigens incorporated into the vesicle structure. This paper reviews different applications in OMV Research and Development (R&D) and provides examples of OMV developed and evaluated at the Finlay Institute in Cuba. A Good Manufacturing Practice (GMP) process was developed at the Finlay Institute to produce OMV from N. meningitidis serogroup B (dOMVB) using detergent extraction. Subsequently, OMV from N. meningitidis, serogroup A (dOMVA), serogroup W (dOMVW) and serogroup X (dOMVX) were obtained using this process. More recently, the extraction process has also been applied effectively for obtaining OMV on a research scale from Vibrio cholerae (dOMVC), Bordetella pertussis (dOMVBP), Mycobacterium smegmatis (dOMVSM) and BCG (dOMVBCG). The immunogenicity of the OMV have been evaluated for specific antibody induction, and together with functional bactericidal and challenge assays in mice have shown their protective potential. dOMVB has been evaluated with non-self neisserial antigens, including with a herpes virus type 2 glycoprotein, ovalbumin and allergens. In conclusion, OMV are proving to be more versatile than first conceived and remain an important technology for development of vaccine candidates. - See more at: http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00121/abstract#sthash.MwqUyZQ1.dpuf",
keywords = "bacterial, outer membrane, vesicles, vaccine applications",
author = "Reinaldo Acevedo and Sonsire Fernandez and Caridad Zayas and Armando Acosta and Sarmiento, {Maria Elena} and Valerie Ferro and Einar Rosenqvist and Concepcion Campa and Daniel Cardoso and Luis Garcia and Perez, {Jose Luis}",
year = "2014",
doi = "10.3389/fimmu.2014.00121#sthash.MwqUyZQ1.dpuf",
language = "English",
volume = "5",
journal = "Frontiers in Immunology",
issn = "1664-3224",
number = "121",

}

Acevedo, R, Fernandez, S, Zayas, C, Acosta, A, Sarmiento, ME, Ferro, V, Rosenqvist, E, Campa, C, Cardoso, D, Garcia, L & Perez, JL 2014, 'Bacterial outer membrane vesicles and vaccine applications' Frontiers in Immunology, vol. 5, no. 121. https://doi.org/10.3389/fimmu.2014.00121#sthash.MwqUyZQ1.dpuf

Bacterial outer membrane vesicles and vaccine applications. / Acevedo, Reinaldo; Fernandez, Sonsire; Zayas, Caridad; Acosta, Armando; Sarmiento, Maria Elena; Ferro, Valerie; Rosenqvist, Einar; Campa, Concepcion ; Cardoso, Daniel; Garcia, Luis; Perez, Jose Luis.

In: Frontiers in Immunology, Vol. 5, No. 121, 2014.

Research output: Contribution to journalSpecial issue

TY - JOUR

T1 - Bacterial outer membrane vesicles and vaccine applications

AU - Acevedo, Reinaldo

AU - Fernandez, Sonsire

AU - Zayas, Caridad

AU - Acosta, Armando

AU - Sarmiento, Maria Elena

AU - Ferro, Valerie

AU - Rosenqvist, Einar

AU - Campa, Concepcion

AU - Cardoso, Daniel

AU - Garcia, Luis

AU - Perez, Jose Luis

PY - 2014

Y1 - 2014

N2 - Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of “self” meningococcal antigens or unrelated antigens incorporated into the vesicle structure. This paper reviews different applications in OMV Research and Development (R&D) and provides examples of OMV developed and evaluated at the Finlay Institute in Cuba. A Good Manufacturing Practice (GMP) process was developed at the Finlay Institute to produce OMV from N. meningitidis serogroup B (dOMVB) using detergent extraction. Subsequently, OMV from N. meningitidis, serogroup A (dOMVA), serogroup W (dOMVW) and serogroup X (dOMVX) were obtained using this process. More recently, the extraction process has also been applied effectively for obtaining OMV on a research scale from Vibrio cholerae (dOMVC), Bordetella pertussis (dOMVBP), Mycobacterium smegmatis (dOMVSM) and BCG (dOMVBCG). The immunogenicity of the OMV have been evaluated for specific antibody induction, and together with functional bactericidal and challenge assays in mice have shown their protective potential. dOMVB has been evaluated with non-self neisserial antigens, including with a herpes virus type 2 glycoprotein, ovalbumin and allergens. In conclusion, OMV are proving to be more versatile than first conceived and remain an important technology for development of vaccine candidates. - See more at: http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00121/abstract#sthash.MwqUyZQ1.dpuf

AB - Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of “self” meningococcal antigens or unrelated antigens incorporated into the vesicle structure. This paper reviews different applications in OMV Research and Development (R&D) and provides examples of OMV developed and evaluated at the Finlay Institute in Cuba. A Good Manufacturing Practice (GMP) process was developed at the Finlay Institute to produce OMV from N. meningitidis serogroup B (dOMVB) using detergent extraction. Subsequently, OMV from N. meningitidis, serogroup A (dOMVA), serogroup W (dOMVW) and serogroup X (dOMVX) were obtained using this process. More recently, the extraction process has also been applied effectively for obtaining OMV on a research scale from Vibrio cholerae (dOMVC), Bordetella pertussis (dOMVBP), Mycobacterium smegmatis (dOMVSM) and BCG (dOMVBCG). The immunogenicity of the OMV have been evaluated for specific antibody induction, and together with functional bactericidal and challenge assays in mice have shown their protective potential. dOMVB has been evaluated with non-self neisserial antigens, including with a herpes virus type 2 glycoprotein, ovalbumin and allergens. In conclusion, OMV are proving to be more versatile than first conceived and remain an important technology for development of vaccine candidates. - See more at: http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00121/abstract#sthash.MwqUyZQ1.dpuf

KW - bacterial

KW - outer membrane

KW - vesicles

KW - vaccine applications

U2 - 10.3389/fimmu.2014.00121#sthash.MwqUyZQ1.dpuf

DO - 10.3389/fimmu.2014.00121#sthash.MwqUyZQ1.dpuf

M3 - Special issue

VL - 5

JO - Frontiers in Immunology

T2 - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - 121

ER -